華潤雙鶴(600062.SH):替格瑞洛片獲批上市
格隆匯4月11日丨華潤雙鶴(600062.SH)公佈,近日,華潤雙鶴藥業股份有限公司收到了國家藥品監督管理局頒發的替格瑞洛片(以下簡稱“該藥品”)《藥品註冊證書》(證書編號爲:2022S00276),批準該藥品生產。
該藥品與阿司匹林合用,用於急性冠脈綜合徵(ACS)患者或有心肌梗死病史且伴有至少一種動脈粥樣硬化血栓形成事件高危因素的患者,降低心血管死亡、心肌梗死和卒中的發生率。
截至公告日,華潤雙鶴針對替格瑞洛片累計研發投入爲人民幣2860.67萬元(未經審計)。
國內市場,根據國家藥監局網站信息顯示,中國大陸境內已批準上市的該藥品生產企業有23家(含華潤雙鶴)。根據米內網數據顯示,2020年國內醫療市場替格瑞洛片銷售總額(終端價)爲16.85億元人民幣,其中市場份額排名前5名的企業分別爲阿斯利康90.92%、深圳信立泰藥業4.2%、南京正大天晴製藥1.92%、石藥歐意藥業1.72%、上海匯倫江蘇藥業0.52%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.